Shimizu Chikako, Fujiwara Yasuhiro
Breast and Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Breast Cancer. 2008;15(2):141-4. doi: 10.1007/s12282-008-0029-0.
There is a clinical demand for tools that could distinguish patients who may benefit or suffer from particular systemic treatments. High throughput technologies such as DNA microarray are anticipated as comprehensive tools for development of accurate predictive markers of treatment outcome. Although technical and statistical problems still exist in pharmacogenomic research, rigorous efforts have been made to realize treatment individualization. Clinicians should be prepared for the future use of these new technologies in the clinic through discussion involving patients and various health-care providers.
对于能够区分哪些患者可能从特定的全身治疗中获益或遭受不良影响的工具存在临床需求。诸如DNA微阵列之类的高通量技术有望成为开发准确的治疗结果预测标志物的综合工具。尽管药物基因组学研究中仍然存在技术和统计学问题，但人们已经做出了严谨的努力来实现治疗个体化。临床医生应通过包括患者和各类医疗服务提供者在内的讨论，为未来在临床中使用这些新技术做好准备。
